BC Week In Review | Jun 6, 2011
Clinical News

CYFRA 21-1 EIA assay regulatory update

Fujirebio's Fujirebio Diagnostics Inc. unit received 510(k) clearance from FDA for its CYFRA 21-1 EIA assay to monitor disease progression in lung cancer patients. The biomarker assay kit that detects soluble cytokeratin 19 ( CK19 ;...
Items per page:
1 - 1 of 1